January 10 hearing contrast medium is one of the essential drugs involved in radiology, also known as contrast agent into the new century, in the field of imaging discipline in the development process, has been X-ray photography, color B- , CT scan imaging gradually extended to the diagnosis and detection of magnetic resonance angiography.
On January 25, 2017, the State Health Planning Commission issued the Notice on Basic Standards and Management Practices of Independently Setting Medical Institutions Such as Medical Imaging Diagnostic Center, which is a good policy for opening a green channel for medical imaging diagnosis and giving medical treatment to China's medical system Bring more opportunities for development, and objectively promote the rapid development of China's contrast media market.
A new generation of contrast agents to promote rigid demand
Contrast Media, commonly known as Contrast Media, is a chemical that is injected into or orally administered to tissues or organs of the human body to enhance the effect of imaging. The density of these products is lower or higher than that of the surrounding tissue. The contrast formed is for some instruments Display image.
With the gradual improvement of the national medical security system, the state and the individual medical and health inputs continue to grow, the medical needs of the accelerated release of the hospital imaging diagnostic equipment technology will also continue to strengthen.A global new generation of contrast agent available, due to its discharge process in the body Little effect on the kidneys, high safety and much favored, thus promoting the replacement of this type of drug.
According to 2017 "National basic medical insurance drug Directory "contained in the category, the contrast agent by iodized X-ray contrast agent, non-iodized X-ray contrast agent, magnetic resonance imaging contrast agent and ultrasound contrast agent four subcategories of 24 varieties, the classification than the previous version Medical insurance directory is more scientific and clear.With the progress of medicine, imaging CT imaging, magnetic resonance imaging and enhanced CT imaging will gradually become an important means of inspection of human tissues and organs, driven by interventional radiology, the potential of the domestic market demand Has surfaced.
Ten billion contrast agent terminals
According to the imaging principle of the device, the contrast agent can be divided into three categories: X-ray contrast agent, magnetic resonance contrast agent and ultrasonic contrast agent, among which X-ray contrast agent and magnetic resonance contrast agent occupy the main market.
According to the statistics from Mynetworks, the amount of contrast media used in public hospitals in key cities in China reached 1.993 billion yuan in 2016, up 13.21% over the previous year. According to the data of the first three quarters of 2017, contrast media in key hospitals in key cities of China in 2017 The amount of 2.655 billion yuan, an increase of 13.67% over the previous year.
Contrast agents and drugs are different, in the three major terminal six markets, urban community health centers, township hospitals, retail pharmacy , The amount of online pharmacies with minimal consumption of major terminals in more than 3,000 domestic public hospitals in the city, more than 10,000 county-level public hospitals, as well as a certain size of the private hospital market.
In the late 1970s, China introduced the new technology of computed tomography (CT). After 50 years, a total of thousands of CT machines of various models were installed in domestic hospitals. The CT examination rapidly expanded nationwide and became Medical diagnosis of indispensable equipment .2009 ~ 2015, China's CT machine installed capacity increased from 9968 to about 20,500 units, an increase of 106%. On the other hand the growth of magnetic resonance imaging equipment can not be underestimated; these Have promoted the contrast agent market development.
According to the "2017 China's deep investigation of the status of the development of the investigation report" shows that China's contrast agent market size compound annual growth rate of over 18%, higher than medicine The overall growth rate of the industry is expected to 2017 domestic contrast agent will exceed 10 billion yuan market size, become a much-watched category.
Figure 1: Contrast agent market in public hospitals in major cities in China in 2016 (Unit: 100 million yuan)
CT contrast agent occupies 80% market share
X-ray contrast agent used in X-ray contrast examination, there are two areas of medical barium sulfate and iodine contrast agent.Medical barium sulfate for the digestive tract contrast, and iodine contrast agent can be used for multiple organs and tissue imaging, the use of More iodine contrast agent types are divided into inorganic iodine contrast agent, organic iodine contrast agent and lipid contrast agent three categories, of which the most widely used organic iodine compounds.
According to the statistics from MyNet, in 2016, CT inspection of contrast media in public hospitals in major cities in China was 1,637 million yuan and will grow to 1.85 billion yuan in 2017, an increase of 13% over the same period of the previous year, accounting for 81.68% of the contrast media market. CT imaging The main varieties of agents are: iodixanol, iohexol, iopromide, ioversol, iopamidol, iodine alcohol, iomeprol, and meglumine diazepam and other compounds.
Figure 2: CT Contrast Agent Market in Major Cities in China in 2016 (Unit: 100 million yuan)
Magnetic resonance imaging market increased year by year
With the improvement of residents' spending power in our country and the concept of "re-diagnosis," more and more people begin to accept CT and magnetic resonance imaging examinations. The proportion of X-ray contrast medium in our country is high, and the direct factor is that many hospitals in China carry out this Examination is the result of continuous expansion of the scope of application and the ever-increasing number of examinations.MR is the means of further examination because of the high cost of testing and the low prevalence of CT compared with that of CT. Data from 2015-2017 show that the number of domestic diagnostic imaging patients has increased rapidly , But there is still huge room for growth.
Magnetic resonance imaging contrast agent mainly by changing the relaxation rate of protons in the local tissue to improve the normal and diseased parts of the imaging contrast to show the functional status of the body organs.According to the parameters of the way the magnetic resonance contrast agent can be divided into Paramagnetic, ferromagnetic and superparamagnetic three categories.
According to the statistics from Mynetworks, the market size of magnetic resonance contrast media in public hospitals in major cities in China was 270 million yuan in 2016 and increased to 294 million yuan in 2017, an increase of 9.03% over the previous year. The main varieties are gadopentetate dimeglumine, gadolinium bis Amine, Gadobeine, Gadoteric acid disodium, Gadoteric acid meglumine, gadobutrol etc. In addition, the increasing popularity of color Doppler ultrasound, and gradually into the community medical treatment, and less use of ultrasound contrast agents, is an affordable primary diagnostic measures .
Figure 3: Magnetic Resonance Imaging Contrast Agents Market in Major Public Hospital in China in 2016 (Unit: 100 million yuan)
Iohexol becomes the gold standard drug
Iohexol is a non-ionic impermeable agent that belongs to the second generation of nonionic monomeric hypotonic contrast agents developed by the Norwegian company Hafslund Nycomed in the mid-1980s and is listed in Norway and Sweden , The brand name 'Omnipaque'. Then passed the US FDA review. Schering-Plow AG sales license in some countries in Europe, has so far in more than 110 countries around the world to promote the use.
Iohexol is a monocyclic nonionic water-soluble X-CT contrast agent with low osmotic pressure and low toxicity to the nervous system. It is a safe contrast agent for intrathecal injection and is widely used in angiography, subarachnoid Computed tomography, coronary angiography, spinal cord and hip joint, urography, CT enhanced scan, which has the advantages of low contrast density, good tolerability, etc., is one of the best contrast agents, developed countries have completely replaced it with Ionico-Contrast Agent After more than two decades of promotion and use, iohexol has become the industry's gold standard drug for evaluating various contrast agents.
According to the CFDA website in August 2017, GE Healthcare AS, Norway, registered iohexol with the trade name "OmniPark", with 55 approvals and 12 formulations enterprise , Domestic raw materials medicine Zhejiang Taitai Li, Zhejiang Haichang, Poseidon, Taizhou, Zhejiang, Aconitum, Guizhou Jingfeng other five, of which Zhejiang Steiner production and sales ranks first.
According to Mi Net data show that in 2016 China's major cities in public hospital Iohexol dosage reached 424 million yuan, an increase of 2.36% over the previous year, TOP200 contrast medium in 89. 2017 will increase to 4.54 billion yuan, an increase of 7.16%. According to the production of various sales point of view , Iohexol market size of 2 billion or so, is the leading domestic contrast medium varieties.
Figure 4: Market of iohexol in public hospitals in major cities in China in 2016 (Unit: 100 million yuan)
Overall, GE Healthcare AS imported less Omnipaque statistics, the backbone of domestic manufacturers of Iohexylone Shanghai GM, Yangtze River Pharmaceutical, Beijing Hokuriku Pharmaceutical and Hansen in Hunan, a total of 98% of the domestic market share.
Iodixanol courageously went straight
Iodixanol is a new generation of contrast agent developed by the United States GE Healthcare Group, was approved by the US FDA in 1996. Its name is Visipaque. In 2001, China approved the registration of iodixanol in China for the purpose of The brand name "Viagra Parker" enters the market, and now the brand is registered in China by GE Healthcare Norway and is distributed and sold by General Electric Pharmaceutical (Shanghai).
Iodixanol is a non-ionic dimer isotonic contrast agent, with clinical concentrations and plasma isotonicity, the incidence of contrast agent nephropathy with low risk and high safety features, is used in high-risk groups of nephrotic angiography agent for Cone tube angiography, intravenous urography and cardiovascular and cerebrovascular angiography, its principle of action is combined with iodine absorption in the blood vessels or tissues caused by X-ray images show that with the development of interventional therapy, iodixanol has potential market demand.
To date, domestic iodixanol raw materials have been registered by Jiangsu Shengdi Pharmaceutical Co., Ltd. and Zhejiang Stella Pharmaceutical Co., Ltd. In November 2010, Hengrui Pharmaceutical's iodixanol first imitation Listed, December 2011 Hokuriku Pharmaceutical obtained production approval.
According to the data from Menetworks, the amount of iodixanol used in the key urban sample hospitals in China in 2016 was over 400 million yuan, an increase of 37.84% over the previous year, which is another rapid growth drug, ranking 107th in the TOP200 variety. Forecast of the first three quarters of 2017, iodixanol will exceed 500 million yuan. Hengrui medicine iodixanol living in first place, accounting for half of GE Healthcare's GE Healthcare, Norway ' (Visipaque) 'accounted for 44.5%, Yangzijiang Pharmaceutical Group accounted for 5.96%, Hokuriku pharmaceutical iodixanol occupy less, the four monopolize the terminal market.
Figure 5: Market of iodixanol in major hospitals in key cities of China in 2016 (Unit: 100 million yuan)
Conclusion
At present, the contrast agent market in China accounts for a relatively small proportion of the global market, but maintains a rapid growth.It is expected that the growth rate of the contrast media industry will remain at around 15% in the future. The main driving factors include industry expansion, import substitution and product upgrading.
